Sun, Sep 21, 2014, 9:27 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • homebuilder_watcher homebuilder_watcher Oct 3, 2012 9:05 AM Flag

    Leerink Swann raises price target to $10

    Vosaroxin Pricing Assumption Review Drives Our New ~$10 DCF
    Valuation: Reit OP
    • Bottom Line: After reviewing pricing of comparable and recently
    approved hematologic therapies, we are increasing our Vosaroxin
    revenue estimates (and DCF valuation) primarily reflecting our increased
    estimated Vosaroxin annual acute myelogenous leukemia (AML)
    treatment cost to $85K (from $75K). We believe this new Vosaroxin
    estimate is more in line with the $80-100K cost of therapies used off label
    in AML (i.e., Dacogen). This drives our new ~$10 DCF valuation (from ~
    $7) based almost entirely from use in relapsed/refractory (RR) AML. We
    currently model no revenue from: (1) front-line (FL) AML, (2) European
    approval, and (3) use in Myelodysplastic Syndrome (MDS), which would
    each provide additional upside to our estimates.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If/when they get European approval for relapsed/refractory AML, this company will have a price target well over 15 probably closer to 18 bucks by unblinding 2014 with positive news.

      MDS is going to be significantly later but if we can get front-line AML status you can add another 10 bucks minimum to the share price.

      Tons of potential for those who will just hold and wait for 1 1/2-2 years.

      Good luck with all your investments.

      Dave

      • 1 Reply to studythosestocks
      • studythosestocks,

        This drug has the potential of outdoing Dendreon in pps at Dendreon's high. This is my opinion. I am not saying this just to hear myself talk. The potential cures/remissions of cancerous illnesses that this drug can participate in is incalculable at this point. This could be your next miracle drug! Strong statement, but look at the possibilities that abound using it in the treatment of different forms of cancer. I am thrilled to have had the faith in this drug from the beginning of my investment in it. Notice I said investment. The traders are gone, the investors are still here.

        Sentiment: Strong Buy

 
SNSS
7.34-0.06(-0.81%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.